Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1159 - 1162
Section III - Un futur en développement
DOI https://doi.org/10.1051/medsci/200925121159
Publié en ligne 15 décembre 2009
  1. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157 : 220–33.
  2. Ward ES, Gussow D, Griffiths AD, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989; 341 : 544–6.
  3. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363 : 446–8.
  4. Greenberg AS, Avila D, Hughes M, et al. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995; 374 : 168–73.
  5. Riechmann L, Muyldermans S. Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods 1999; 231 : 25–38.
  6. Famm K, Hansen L, Christ D, Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol 2008; 376 : 926–31.
  7. Dumoulin M, Conrath K, Van Meirhaeghe A, et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002; 11 : 500–15.
  8. Tanaka T, Lobato MN, Rabbitts TH. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. J Mol Biol 2003; 331 : 1109–20.
  9. Su C, Nguyen VK, Nei M. Adaptive evolution of variable region genes encoding an unusual type of immunoglobulin in camelids. Mol Biol Evol 2002; 19 : 205–15.
  10. Vincke C, Loris R, Saerens D, et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 2009; 284 : 3273–84.
  11. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998; 17 : 3512–20.
  12. Stijlemans B, Conrath K, Cortez-Retamozo V, et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 2004; 279 : 1256–61.
  13. Goldman ER, Anderson GP, Liu JL, et al. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal Chem 2006; 78 : 8245–55.
  14. Roovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 2007; 56 : 303–17.
  15. Kubetzko S, Balic E, Waibel R, et al. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 2006; 281 : 35186–201.
  16. Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 2008; 7 : 2288–97.
  17. Zhang J, Tanha J, Hirama T, et al. Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol 2004; 335 : 49–56.
  18. Stone E, Hirama T, Tanha J, et al. The assembly of single domain antibodies into bispecific decavalent molecules. J Immunol Methods 2007; 318 : 88–94.
  19. Behar G, Siberil S, Groulet A, et al. Isolation and characterization of anti-Fc gamma RIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2008; 21 : 1–10.
  20. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004; 64 : 2853–7.
  21. Miller TW, Messer A. Intrabody applications in neurological disorders: progress and future prospects. Mol Ther 2005; 12 : 394–401.
  22. Wingren C, Borrebaeck CA. Progress in miniaturization of protein arrays: a step closer to high-density nanoarrays. Drug Discov Today 2007; 12 : 813–9.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.